BARBA, MADDALENA
 Distribuzione geografica
Continente #
NA - Nord America 944
EU - Europa 327
AS - Asia 94
AF - Africa 7
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1.374
Nazione #
US - Stati Uniti d'America 933
SE - Svezia 110
IT - Italia 97
IN - India 46
FI - Finlandia 36
DE - Germania 29
SG - Singapore 23
GB - Regno Unito 18
CN - Cina 16
CA - Canada 11
BG - Bulgaria 8
IE - Irlanda 8
RO - Romania 7
IR - Iran 5
TG - Togo 5
FR - Francia 4
CH - Svizzera 3
UA - Ucraina 3
HK - Hong Kong 2
NL - Olanda 2
AR - Argentina 1
EE - Estonia 1
EU - Europa 1
GR - Grecia 1
JP - Giappone 1
SC - Seychelles 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 1.374
Città #
Fairfield 163
Ashburn 74
Seattle 68
Cambridge 66
Chandler 61
Houston 59
Woodbridge 54
Wilmington 50
Rome 33
Helsinki 32
Princeton 30
Dearborn 26
San Paolo di Civitate 22
New York 21
Millbury 17
Ann Arbor 15
Lawrence 15
Sacramento 14
Bremen 13
San Diego 12
Andover 11
Plano 10
Ottawa 8
Sofia 8
Singapore 7
Surrey 7
Boston 6
Dublin 6
Norwalk 6
Beijing 5
Bühl 5
Lomé 5
Boardman 3
Glasgow 3
Guangzhou 3
Torino 3
Birmingham 2
Bovisio-Masciago 2
Falls Church 2
Fort Worth 2
Hong Kong 2
Leawood 2
Liverpool 2
Livorno 2
Magenta 2
Palermo 2
Phoenix 2
Redwood City 2
Shenyang 2
Toronto 2
Trumbull 2
Zanjan 2
Augusta 1
Bangkok 1
Berlin 1
Bern 1
Buffalo 1
Catania 1
Dallas 1
Edinburgh 1
Falkenstein 1
Federal 1
Frattamaggiore 1
Fremont 1
Frosinone 1
Fuzhou 1
Groningen 1
Guidonia 1
Guidonia Montecelio 1
Hefei 1
Henderson 1
Kashan 1
Kish 1
Lappeenranta 1
Levallois-perret 1
Los Angeles 1
Menlo Park 1
Milan 1
Muizenberg 1
Naples 1
Quzhou 1
Riva 1
San Mateo 1
Shanghai 1
Southend 1
Tallinn 1
Thessaloniki 1
Vigonza 1
Winnipeg 1
Zhengzhou 1
Totale 1.011
Nome #
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience 116
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 103
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study 96
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 94
Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer 88
Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients 81
Neoadjuvant sequential docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab. The DECT trial 67
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome 62
Autoantibodies specific to ERa are involved in tamoxifen resistance in hormone receptor positive breast cancer 60
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 57
KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy 55
null 54
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden 54
null 52
Neoadjuvant immune-checkpoint blockade in triple-negative breast cancer: current evidence and literature-based meta-analysis of randomized trials 50
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes 46
null 39
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience 37
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 33
Observational multicenter study on the prognostic relevance of coagulation activation in risk assessment and stratification in locally advanced breast cancer. Outline of the arias trial 32
Circulating hpv dna in the management of oropharyngeal and cervical cancers: current knowledge and future perspectives 28
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial 28
GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer 22
null 21
Burnout of health care providers during the covid-19 pandemic: Focus on medical oncologists 19
Biomarkers of response and resistance to CDK4/6 inhibitors in breast cancer: hints from liquid biopsy and microRNA exploration 18
Prognostic relevance of neutrophil to lymphocyte ratio (Nlr) in luminal breast cancer: A retrospective analysis in the neoadjuvant setting 17
Neoadjuvant endocrine therapy in breast cancer. Current knowledge and future perspectives 17
How Dual-Energy Contrast-Enhanced Spectral Mammography Can Provide Useful Clinical Information About Prognostic Factors in Breast Cancer Patients: A Systematic Review of Literature 16
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 15
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study 14
Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer 12
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study 11
Indirect basal metabolism estimation in tailoring recombinant human TSH administration in patients affected by differentiated thyroid cancer: A hypothesis-generating study 10
Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors 7
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study 3
Totale 1.534
Categoria #
all - tutte 4.623
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.623


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201993 0 0 0 0 0 0 0 0 0 15 34 44
2019/2020337 26 10 8 10 38 51 47 41 43 29 19 15
2020/2021152 24 9 8 9 4 11 0 5 13 54 12 3
2021/2022324 3 5 15 18 63 23 4 23 12 20 93 45
2022/2023397 85 67 28 27 54 35 14 38 27 8 10 4
2023/2024184 6 24 12 18 26 32 1 37 5 23 0 0
Totale 1.534